1. Home
  2. TOI vs SGMT Comparison

TOI vs SGMT Comparison

Compare TOI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOI
  • SGMT
  • Stock Information
  • Founded
  • TOI 2007
  • SGMT 2006
  • Country
  • TOI United States
  • SGMT United States
  • Employees
  • TOI N/A
  • SGMT N/A
  • Industry
  • TOI Medical/Nursing Services
  • SGMT
  • Sector
  • TOI Health Care
  • SGMT
  • Exchange
  • TOI Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • TOI 266.8M
  • SGMT 269.2M
  • IPO Year
  • TOI N/A
  • SGMT 2023
  • Fundamental
  • Price
  • TOI $2.07
  • SGMT $7.68
  • Analyst Decision
  • TOI
  • SGMT Strong Buy
  • Analyst Count
  • TOI 0
  • SGMT 6
  • Target Price
  • TOI N/A
  • SGMT $23.17
  • AVG Volume (30 Days)
  • TOI 2.2M
  • SGMT 3.6M
  • Earning Date
  • TOI 08-12-2025
  • SGMT 08-13-2025
  • Dividend Yield
  • TOI N/A
  • SGMT N/A
  • EPS Growth
  • TOI N/A
  • SGMT N/A
  • EPS
  • TOI N/A
  • SGMT N/A
  • Revenue
  • TOI $403,152,000.00
  • SGMT N/A
  • Revenue This Year
  • TOI $23.95
  • SGMT N/A
  • Revenue Next Year
  • TOI N/A
  • SGMT N/A
  • P/E Ratio
  • TOI N/A
  • SGMT N/A
  • Revenue Growth
  • TOI 17.64
  • SGMT N/A
  • 52 Week Low
  • TOI $0.13
  • SGMT $1.73
  • 52 Week High
  • TOI $3.50
  • SGMT $10.43
  • Technical
  • Relative Strength Index (RSI)
  • TOI 39.47
  • SGMT 66.04
  • Support Level
  • TOI $2.09
  • SGMT $6.56
  • Resistance Level
  • TOI $2.87
  • SGMT $10.43
  • Average True Range (ATR)
  • TOI 0.21
  • SGMT 1.32
  • MACD
  • TOI -0.07
  • SGMT 0.21
  • Stochastic Oscillator
  • TOI 18.29
  • SGMT 70.03

About TOI The Oncology Institute Inc.

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: